Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema | MicrobiomeTrials← Back to trialsNCT05355818
Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema
CompletedPHASE3INTERVENTIONAL
Trial Details
Start: 2022-07-14Est. Completion: 2024-12-05
Enrollment target: 98 participants Locations- LEO Pharma investigational site, Darlinghurst, Australia
- LEO Pharma investigational site, Mitcham, Australia
- LEO Pharma investigational site, Phillip, Australia
- LEO Pharma investigational site, Woolloongabba, Australia
- LEO Pharma investigational site, Brussels, Belgium
- LEO Pharma investigational site, Ghent, Belgium
- LEO Pharma investigational site, Gilly, Belgium
- LEO Pharma investigational site, Liège, Belgium
- LEO Pharma investigational site, Edmonton, Canada
- LEO Pharma investigational site, Fredericton, Canada
- LEO Pharma investigational site, Kingston, Canada
- LEO Pharma investigational site, Montreal, Canada
- LEO Pharma investigational site, Red Deer, Canada
- LEO Pharma investigational site, St. John's, Canada
- LEO Pharma investigational site, Toronto, Canada
- LEO Pharma investigational site, Winnipeg, Canada
- LEO Pharma investigational site, Martigues, Bouches-du-Rhône, France
- LEO Pharma investigational site, Nice, France
Other microbiome trials you might be interested in
Chronic Hand Eczema
The design is a prospective, observational registry for subjects with CHE under the care of dermatology or other qualifi…
Multiple LocationsEst. completion Dec 31, 2099
Chronic Hand Eczema (CHE)
The goal of this non-interventional study is to assess changes in the signs and symptoms of Chronic Hand Eczema (CHE), a…
Neu-Isenburg, GermanyCompleted Dec 31, 2029
LEO Pharma investigational site, Reims, FranceLEO Pharma investigational site, Toulouse, FranceLEO Pharma investigational site, Chorzów, PolandLEO Pharma investigational site, Krakow, PolandLEO Pharma investigational site, Krakow, PolandLEO Pharma investigational site, Krakow, PolandLEO Pharma investigational site, Warsaw, PolandLEO Pharma investigational site, Wroclaw, PolandLEO Pharma investigational site, Alicante, SpainLEO Pharma investigational site, Barcelona, SpainLEO Pharma investigational site, Cadiz, SpainLEO Pharma investigational site, Esplugues de Llobregat, SpainLEO Pharma investigational site, Fuenlabrada, SpainLEO Pharma investigational site, Granada, SpainLEO Pharma investigational site, Ipswich, United KingdomLEO Pharma investigational site, Kings Lynn, United KingdomLEO Pharma investigational site, Lincoln, United KingdomLEO Pharma investigational site, London, United KingdomLEO Pharma investigational site, Walsall, United KingdomPierre Fabre Laboratories have developed a cream with medical device status, RV4421B-EV0407 indicated for the treatment …
Quatre Bornes, MauritiusEst. completion Nov 2026